RAPP

Rapport Therapeutics, Inc. (RAPP) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders using its RAP (Receptor Associated Protein) technology platform. The company's lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator being evaluated for focal onset seizures, bipolar disorder, and diabetic peripheral neuropathic pain (DPNP). The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Raise: In September 2025, the company completed an underwritten public offering of 11,057,692 shares at $26.00 per share, raising net proceeds of approximately $269.4 million. This significantly increased liquidity compared to the prior year.
• Expense Growth: Total operating expenses increased by 38.6% in Q3 2025 compared to Q3 2024 ($29.9M vs. $21.6M). R&D expenses rose 43% primarily due to increased clinical trial costs for the Phase 2a trial in focal onset seizures and the Phase 2 trial in bipolar mania.
• Net Loss: Net loss for the nine months ended September 30, 2025, was $77.7 million, compared to $58.3 million in the same period in 2024. The increase is driven by higher operating expenses, partially offset by the absence of a $7.4 million non-cash expense related to the change in fair value of preferred stock tranche right liability recorded in 2024.
• Liquidity Position: Cash and cash equivalents increased from $56.8 million at year-end 2024 to $251.4 million at September 30, 2025, bolstered by the September 2025 offering.

Guidance, Outlook, and Risks

• Clinical Progress:
  • Focal Onset Seizures: Announced positive topline results from the Phase 2a proof-of-concept trial in September 2025, meeting primary and secondary endpoints. Plans to initiate an open-label long-term safety trial by end of 2025 and hold an end-of-Phase 2 meeting with the FDA in Q4 2025. Phase 3 initiation expected in Q3 2026.
  • Bipolar Mania: Phase 2 proof-of-concept trial is currently enrolling; topline results expected in H1 2027.
  • DPNP: The IND for the Phase 2 trial in diabetic peripheral neuropathic pain remains on clinical hold by the FDA. The FDA requested additional information regarding protocol design. Next steps are expected to be determined in Q1 2026.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments ($513.0 million) are sufficient to fund operations and capital expenditures into the second half of 2029.
• Key Risks:
  • Regulatory Holds: Continued clinical hold on the DPNP program could delay development or require significant protocol changes.
  • Capital Requirements: Despite recent funding, the company expects to incur significant losses for the foreseeable future and will require additional financing to support late-stage trials and commercialization.
  • Third-Party Dependence: Reliance on NeuroPace for data collection in seizure trials and third-party manufacturers for drug supply.
  • Intellectual Property: Dependence on in-licensed IP from Janssen Pharmaceutical NV, subject to milestone payments and royalty obligations.

Investor Verification Checklist

• Verify the status of the FDA clinical hold on the RAP-219 DPNP program and the timeline for resolution.
• Confirm the specific milestone payment obligations under the Janssen license agreement and their impact on future cash flow.
• Review the detailed Phase 2a seizure trial data to assess the robustness of the primary endpoint (long episodes reduction) and its translatability to registrational trials.
• Monitor the company's burn rate and cash runway relative to the projected timeline for Phase 3 initiation in 2026.
• Assess the manufacturing supply chain risks, particularly regarding third-party manufacturers located outside the U.S.